Eric Shaff, Seres Therapeutics CEO
June 6, 2024 07:00 AM EDT
Deals

To pay off debt and stay open, Seres will sell mi­cro­bio­me pill to part­ner Nestlé

Ryan Cross

Senior Science Correspondent

Seres Ther­a­peu­tics has signed an agree­ment with its com­mer­cial­iza­tion part­ner Nestlé Health Sci­ence to sell the re­main­ing rights to its mi­cro­bio­me pill and fo­cus on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times